U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H13Cl2NO4
Molecular Weight 354.1852
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACECLOFENAC

SMILES

c1ccc(c(c1)CC(=O)OCC(=O)O)Nc2c(cccc2Cl)Cl

InChI

InChIKey=MNIPYSSQXLZQLJ-UHFFFAOYSA-N
InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)

HIDE SMILES / InChI

Molecular Formula C16H13Cl2NO4
Molecular Weight 354.1852
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The dose is 100 mg twice daily, and should not be given to people with porphyria or breastfeeding mothers and is not recommended for children. Aceclofenac is a cytokine inhibitor. Aceclofenac works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of prostaglandins (chemicals in the body which cause pain, swelling and inflammation). Aceclofenac is the glycolic acid ester of diclofenac. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower than that of other frequently prescribed NSAIDs: for instance, 2-fold less than naproxen, 4-fold less than diclofenac, and 7-fold less than indomethacin. Aceclofenac is metabolized in human hepatocytes and human microsomes to form [2-(2',6'-dichloro-4'-hydroxy- phenylamino)phenyl] acetoxyacetic acid as the major metabolite, which is then further conjugated.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Clanza CR

Approved Use

CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism.

Launch Date

1.30515835E12
Palliative
Clanza CR

Approved Use

CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism.

Launch Date

1.30515835E12
Palliative
Clanza CR

Approved Use

CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism.

Launch Date

1.30515835E12
Palliative
Clanza CR

Approved Use

CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism.

Launch Date

1.30515835E12
PubMed

PubMed

TitleDatePubMed
In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators.
2001 Aug
Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes.
2001 Dec
[What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?].
2001 Jul
In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs).
2001 May
[Toxic hepatitis caused by aceclofenac].
2001 Oct
Photoallergic contact dermatitis from aceclofenac.
2001 Sep
Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain.
2002
Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review.
2002 Aug
Preparation and evaluation of aceclofenac microemulsion for transdermal delivery system.
2002 Aug
Determination of aceclofenac in bulk and pharmaceutical formulations.
2002 Jan 1
Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes.
2002 Jul
Stability-indicating spectrophotometric and densitometric methods for determination of aceclofenac.
2002 May
[Acid coxibs, NO donors, cytokine inhibitors. New beginnings against rheumatism].
2002 Nov 28
Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs.
2002 Oct 11
[Exudative erythema multiforme with transition to a toxic epidermal necrolysis after taking aceclofenac (Beofenac)].
2003 Mar 7
Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.
2004
Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets (Aceclofar and Bristaflam) in healthy human volunteers.
2004 Apr
Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality?
2004 Jun
Pain and osteoarthritis: new drugs and mechanisms.
2004 Sep
Polarographic behaviour of Aceclofenac, Tenoxicam and Droxicam in a methanol-water mixture.
2004 Sep 21
Comparative efficacy of aceclofenac and etoricoxib in post extraction pain control: randomized control trial.
2005 Apr-Jun
Stability of response characteristics of a Delphi panel: application of bootstrap data expansion.
2005 Dec 1
Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617].
2005 Nov 10
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population.
2005 Nov 29
Formulation of microemulsion systems for transdermal delivery of aceclofenac.
2005 Sep
Effect of processing variables on micro particulate system of aceclofenac.
2006 Jan
Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars.
2006 Jun
Consumption costs of inappropriate medicines estimated from bulk purchase data: The example of NSAids in Guatemala.
2006 Nov
Evaluation of bioequivalence of two formulations containing 100 milligrams of aceclofenac.
2006 Nov-Dec
Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial.
2007 Aug
Nanoemulsions as vehicles for transdermal delivery of aceclofenac.
2007 Dec 14
Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac.
2007 Feb
Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses.
2007 Jan
Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies.
2007 Jul
[After taking non-steroidal anti-inflammatory agents. What is the cause of the "blue spot?" ].
2007 Jul 19
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom.
2007 Jun
Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY.
2007 Mar
Photodegradation and in vitro phototoxicity of aceclofenac.
2007 May
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?
2007 May
Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers.
2008 Apr
Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene.
2008 Apr 15
Simultaneous determination of aceclofenac, paracetamol, and chlorzoxazone by RP-HPLC in pharmaceutical dosage form.
2008 Aug
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.
2008 Dec
Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry.
2008 Feb 13
Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach.
2008 Feb 28
Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease.
2008 Feb 29
Mathematical evaluation of similarity factor using various weighing approaches on aceclofenac marketed formulations by model-independent method.
2008 Jan
Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion.
2008 Jul 9
Preventing peridural fibrosis with nonsteroidal anti-inflammatory drugs.
2008 Mar
Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.
2008 Oct
Patents

Sample Use Guides

is 200 mg daily, taken as one dose (every 24 hours).
Route of Administration: Oral
In Vitro Use Guide
In vitro adhesion assays were developed to examine the effects of aceclofenac on both neutrophil adhesion to tumor necrosis factor alpha stimulated human umbilical vein endothelial cells under nonstatic conditions, and homotypic neutrophil aggregation induced by anti-ICAM-3 and anti-CD18 monoclonal antibodies (Mab)
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:15:41 UTC 2021
Edited
by admin
on Fri Jun 25 21:15:41 UTC 2021
Record UNII
RPK779R03H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACECLOFENAC
EP   INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
ACECLOFENAC [EP MONOGRAPH]
Common Name English
ACECLOFENAC [MART.]
Common Name English
GLYCOLIC ACID, (O-(2,6-DICHLOROANILINO)PHENYL)ACETATE (ESTER)
Common Name English
ACECLOFENAC BETADEX [WHO-DD]
Common Name English
ACECLOFENAC [MI]
Common Name English
ACECLOFENAC [INN]
Common Name English
ACECLOFENAC [WHO-DD]
Common Name English
ACECLOFENAC [JAN]
Common Name English
Classification Tree Code System Code
WHO-VATC QM02AA25
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
WHO-ATC M02AA25
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
WHO-VATC QM01AB16
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
WHO-ATC M01AB16
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C80534
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
MERCK INDEX
M1293
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY Merck Index
FDA UNII
RPK779R03H
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
PUBCHEM
71771
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
RXCUI
16689
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
43
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
WIKIPEDIA
ACECLOFENAC
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
INN
5608
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL93645
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
CAS
89796-99-6
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
EVMPD
SUB05200MIG
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
EPA CompTox
89796-99-6
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
MESH
C056498
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
DRUG BANK
DB06736
Created by admin on Fri Jun 25 21:15:41 UTC 2021 , Edited by admin on Fri Jun 25 21:15:41 UTC 2021
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY